** Qurevo® (ombitasvir / paritaprevir / ritonavir) 12.5 mg / 75 mg / 50 mg 28 film-coated tablets. Oral use.
Each film-coated tablet contains:
ombitasvir 12.5 mg + paritaprevir 75 mg + ritonavir 50 mg (as a pharmacokinetic enhancer).
indicated for the treatment of adult patients with chronic hepatitis C virus (HCV).
** Mechanism of Action:
It combines three direct-acting hepatitis C virus antiviral agents with distinct mechanisms of action.
Ritonavir is not active against HCV. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of paritaprevir and overall drug exposure (i.e., area under the curve).
** Medicinal product subject to medical prescription.
** Read the package leaflet before use.
** Store below 30 degrees C.
Keep out of the sight and reach of children.